Collaborative Applications of the BrainCells Platform
- Evaluate existing CNS development portfolio for additional clinical indications as individual compounds and in combination with other agents
- Help define Phase 2 dose selection for Phase 1 development programs
- Navigate drug-drug interactions for clinical development programs
- Screen early stage development candidates for neurogenesis activity
- Evaluate new chemical entities from medicinal chemistry effort against novel targets
R&D Collaboration
BrainCells is seeking to collaborate with select biopharmaceutical companies to apply its neurogenesis platform to CNS portfolio prioritization and optimization challenges at various stages.
Development
Combine your resources and expertise with BrainCells’ proprietary technology, know-how and CNS knowledge to identify new targets and compounds for the treatment of CNS disorders.
Augmentation
Employ BrainCells’ proprietary technology to improve the clinical efficacy or reduce side effects of your compound by shifting its neurogenic profile or identifying alternative indications. Such collaborations may include identifying novel combinations of approved drugs that exhibit synergistic neurogenic profiles.
Profiling
Screen your qualified compound library comprising discovery through clinical stage compounds to identify those compounds that modulate neurogenesis.
Direct collaboration inquiries to Jason Levin, Chief Business Officer: jlevin@braincellsinc.com